HMG-CoA reductase inhibitors: an exciting development in the treatment of hyperlipoproteinemia.
Kathawala
F G
FG
Preclinical Research Department, Sandoz Research Institute, East Hanover, New Jersey 07936.
D000818:Animals; D005229:Fatty Acids, Monounsaturated / Q000138:chemical synthesis / Q000737:chemistry / Q000493:pharmacokinetics; D000077340:Fluvastatin; D006801:Humans; D006904:Hydroxymethylglutaryl-CoA Synthase / Q000037:antagonists & inhibitors*; D006951:Hyperlipoproteinemias / Q000188:drug therapy*; D007211:Indoles / Q000138:chemical synthesis / Q000737:chemistry / Q000493:pharmacokinetics; D008074:Lipoproteins / Q000097:blood
D005229:Fatty Acids, Monounsaturated; D007211:Indoles; D008074:Lipoproteins; D000077340:Fluvastatin; D006904:Hydroxymethylglutaryl-CoA Synthase